Near-infrared-activated polymer photosensitizer YBS and PD-1/PD-L1 complex inhibitor BMS-202 were encapsulated in a targeted NP to treat PCa in vivo and in vitro.This therapy generates a strong immune response against tumors, halting primary tumor progression and preventing tumor relapse and metastasis through long-term immune memory. Here, PDCD1 is linked to neoplasm.